logo
Share SHARE
FONT-SIZE Plus   Neg

MorphoSys And Novozymes Sign Long-Term Alliance On Slonomics Technology

MorphoSys AG (MPSYY.PK) and Novozymes A/S Thursday said they have signed a multi-year licensing and technology transfer agreement. The agreement provides Novozymes with a non-exclusive license to use MorphoSys's proprietary Slonomics technology to develop novel products within the industrial biotechnology sector.

Novozymes becomes the first industrial biotech company to have access to Slonomics technology. Financial details were not disclosed.

Slonomics technology, which comprises patented methods and know-how, advanced materials and robotic equipment, allows combination of building blocks in exactly the preferred order and composition. Researchers can thus create only the desired diversity among a set of enzyme variants, eliminating all the undesired combinations. In a typical scenario, Novozymes' researchers can reduce the number of variants made from millions to ten thousand.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
TerraForm Global, Inc., an operator of clean energy power plants, said Monday that it has signed an exclusivity agreement with Brookfield Asset Management Inc. to negotiate a potential business combination between them. Shares of TerraForm Global are gaining more than 6 percent in pre-market activity following the announcement. Fast food giant McDonald's Corp. (MCD) on Monday reported a 1 percent decline in profit for the fourth quarter from last year on lower revenues due to the impact of refranchising. However, both revenue and earnings per share beat analysts' expectations. The Oak Brook, Illinois-based hamburger chain... U.S. authorities are investigating Yahoo Inc. for not disclosing the two massive data breaches sooner to investors, the Wall Street Journal reported, citing people familiar with the matter. It is expected that such a move could help clarify the timeline for companies to reveal such hacks.
comments powered by Disqus
Follow RTT